Cancer Drug based PARP Inhibitor Market
1 Study Coverage
1.1 Cancer Drug based on PARP Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.3 Market by Application
1.3.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts 2017-2028
2.2 Global Cancer Drug based on PARP Inhibitor Revenue Estimates and Forecasts 2017-2028
2.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Cancer Drug based on PARP Inhibitor Sales by Region
2.4.1 Global Cancer Drug based on PARP Inhibitor Sales by Region (2017-2022)
2.4.2 Global Sales Cancer Drug based on PARP Inhibitor by Region (2023-2028)
2.5 Global Cancer Drug based on PARP Inhibitor Revenue by Region
2.5.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2022)
2.5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers
3.1.1 Global Top Cancer Drug based on PARP Inhibitor Manufacturers by Sales (2017-2022)
3.1.2 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Drug based on PARP Inhibitor in 2021
3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers
3.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2017-2022)
3.2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Drug based on PARP Inhibitor Revenue in 2021
3.3 Global Cancer Drug based on PARP Inhibitor Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Cancer Drug based on PARP Inhibitor Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Drug based on PARP Inhibitor Sales by Type
4.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Type (2017-2022)
4.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Type (2023-2028)
4.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
4.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type
4.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Type (2017-2022)
4.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Type (2023-2028)
4.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
4.3 Global Cancer Drug based on PARP Inhibitor Price by Type
4.3.1 Global Cancer Drug based on PARP Inhibitor Price by Type (2017-2022)
4.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Cancer Drug based on PARP Inhibitor Sales by Application
5.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Application (2017-2022)
5.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Application (2023-2028)
5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application
5.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Application (2017-2022)
5.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Application (2023-2028)
5.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
5.3 Global Cancer Drug based on PARP Inhibitor Price by Application
5.3.1 Global Cancer Drug based on PARP Inhibitor Price by Application (2017-2022)
5.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Application (2023-2028)
6 North America
6.1 North America Cancer Drug based on PARP Inhibitor Market Size by Type
6.1.1 North America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
6.1.2 North America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
6.2 North America Cancer Drug based on PARP Inhibitor Market Size by Application
6.2.1 North America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
6.2.2 North America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
6.3 North America Cancer Drug based on PARP Inhibitor Market Size by Country
6.3.1 North America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
6.3.2 North America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Type
7.1.1 Europe Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
7.1.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
7.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Application
7.2.1 Europe Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
7.2.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
7.3 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
7.3.1 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
7.3.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Type
8.1.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
8.1.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
8.2 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Application
8.2.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
8.2.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
8.3 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Region
8.3.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2017-2028)
8.3.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Cancer Drug based on PARP Inhibitor Market Size by Type
9.1.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
9.1.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
9.2 Latin America Cancer Drug based on PARP Inhibitor Market Size by Application
9.2.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
9.2.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
9.3 Latin America Cancer Drug based on PARP Inhibitor Market Size by Country
9.3.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
9.3.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Type
10.1.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
10.1.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
10.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Application
10.2.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
10.2.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
10.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country
10.3.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
10.3.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Corporation Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Overview
11.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GSK Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GSK Recent Developments
11.4 Clovis Oncology
11.4.1 Clovis Oncology Corporation Information
11.4.2 Clovis Oncology Overview
11.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Clovis Oncology Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
11.6 Zai Lab
11.6.1 Zai Lab Corporation Information
11.6.2 Zai Lab Overview
11.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zai Lab Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Drug based on PARP Inhibitor Industry Chain Analysis
12.2 Cancer Drug based on PARP Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Drug based on PARP Inhibitor Production Mode & Process
12.4 Cancer Drug based on PARP Inhibitor Sales and Marketing
12.4.1 Cancer Drug based on PARP Inhibitor Sales Channels
12.4.2 Cancer Drug based on PARP Inhibitor Distributors
12.5 Cancer Drug based on PARP Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Cancer Drug based on PARP Inhibitor Industry Trends
13.2 Cancer Drug based on PARP Inhibitor Market Drivers
13.3 Cancer Drug based on PARP Inhibitor Market Challenges
13.4 Cancer Drug based on PARP Inhibitor Market Restraints
14 Key Findings in The Global Cancer Drug based on PARP Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Lynparza
Table 3. Major Manufacturers of Zejula
Table 4. Major Manufacturers of Rubraca
Table 5. Major Manufacturers of Talzenna
Table 6. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Cancer Drug based on PARP Inhibitor Sales by Region (2017-2022) & (K Units)
Table 9. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2017-2022)
Table 10. Global Cancer Drug based on PARP Inhibitor Sales by Region (2023-2028) & (K Units)
Table 11. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2023-2028)
Table 12. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2017-2022)
Table 14. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2023-2028)
Table 16. Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Cancer Drug based on PARP Inhibitor Sales Share by Manufacturers (2017-2022)
Table 18. Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers (2017-2022)
Table 20. Cancer Drug based on PARP Inhibitor Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Cancer Drug based on PARP Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug based on PARP Inhibitor as of 2021)
Table 23. Cancer Drug based on PARP Inhibitor Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Cancer Drug based on PARP Inhibitor Product Offered
Table 25. Date of Manufacturers Enter into Cancer Drug based on PARP Inhibitor Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 28. Global Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 29. Global Cancer Drug based on PARP Inhibitor Sales Share by Type (2017-2022)
Table 30. Global Cancer Drug based on PARP Inhibitor Sales Share by Type (2023-2028)
Table 31. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Cancer Drug based on PARP Inhibitor Revenue Share by Type (2017-2022)
Table 34. Global Cancer Drug based on PARP Inhibitor Revenue Share by Type (2023-2028)
Table 35. Cancer Drug based on PARP Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Cancer Drug based on PARP Inhibitor Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 38. Global Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 39. Global Cancer Drug based on PARP Inhibitor Sales Share by Application (2017-2022)
Table 40. Global Cancer Drug based on PARP Inhibitor Sales Share by Application (2023-2028)
Table 41. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Cancer Drug based on PARP Inhibitor Revenue Share by Application (2017-2022)
Table 44. Global Cancer Drug based on PARP Inhibitor Revenue Share by Application (2023-2028)
Table 45. Cancer Drug based on PARP Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Cancer Drug based on PARP Inhibitor Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 48. North America Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 49. North America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 52. North America Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 53. North America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2022) & (K Units)
Table 56. North America Cancer Drug based on PARP Inhibitor Sales by Country (2023-2028) & (K Units)
Table 57. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Cancer Drug based on PARP Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 60. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 61. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 64. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 65. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2017-2022) & (K Units)
Table 68. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2023-2028) & (K Units)
Table 69. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 107. AstraZeneca Corporation Information
Table 108. AstraZeneca Description and Major Businesses
Table 109. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. AstraZeneca Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. AstraZeneca Recent Developments
Table 112. Merck & Co Corporation Information
Table 113. Merck & Co Description and Major Businesses
Table 114. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Merck & Co Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Merck & Co Recent Developments
Table 117. GSK Corporation Information
Table 118. GSK Description and Major Businesses
Table 119. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. GSK Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. GSK Recent Developments
Table 122. Clovis Oncology Corporation Information
Table 123. Clovis Oncology Description and Major Businesses
Table 124. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Clovis Oncology Recent Developments
Table 127. Pfizer Corporation Information
Table 128. Pfizer Description and Major Businesses
Table 129. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Pfizer Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Pfizer Recent Developments
Table 132. Zai Lab Corporation Information
Table 133. Zai Lab Description and Major Businesses
Table 134. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Zai Lab Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Zai Lab Recent Developments
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Cancer Drug based on PARP Inhibitor Distributors List
Table 140. Cancer Drug based on PARP Inhibitor Customers List
Table 141. Cancer Drug based on PARP Inhibitor Market Trends
Table 142. Cancer Drug based on PARP Inhibitor Market Drivers
Table 143. Cancer Drug based on PARP Inhibitor Market Challenges
Table 144. Cancer Drug based on PARP Inhibitor Market Restraints
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Drug based on PARP Inhibitor Product Picture
Figure 3. Global Cancer Drug based on PARP Inhibitor Market Share by Type in 2021 & 2028
Figure 3. Lynparza Product Picture
Figure 4. Zejula Product Picture
Figure 5. Rubraca Product Picture
Figure 6. Talzenna Product Picture
Figure 7. Global Cancer Drug based on PARP Inhibitor Market Share by Application in 2021 & 2028
Figure 8. Ovarian Cancer
Figure 9. Breast Cancer
Figure 10. Other
Figure 11. Cancer Drug based on PARP Inhibitor Report Years Considered
Figure 12. Global Cancer Drug based on PARP Inhibitor Sales 2017-2028 (K Units)
Figure 13. Global Cancer Drug based on PARP Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Cancer Drug based on PARP Inhibitor Revenue 2017-2028 (US$ Million)
Figure 15. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2017-2022)
Figure 17. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2023-2028)
Figure 18. North America Cancer Drug based on PARP Inhibitor Sales YoY (2017-2028) & (K Units)
Figure 19. North America Cancer Drug based on PARP Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Cancer Drug based on PARP Inhibitor Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Cancer Drug based on PARP Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Cancer Drug based on PARP Inhibitor Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Cancer Drug based on PARP Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Cancer Drug based on PARP Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Cancer Drug based on PARP Inhibitor in the World: Market Share by Cancer Drug based on PARP Inhibitor Revenue in 2021
Figure 30. Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 32. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 33. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 34. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 35. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 36. North America Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 37. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 38. North America Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 39. North America Cancer Drug based on PARP Inhibitor Sales Share by Country (2017-2028)
Figure 40. North America Cancer Drug based on PARP Inhibitor Revenue Share by Country (2017-2028)
Figure 41. United States Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 44. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 45. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 46. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 47. Europe Cancer Drug based on PARP Inhibitor Sales Share by Country (2017-2028)
Figure 48. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Country (2017-2028)
Figure 49. Germany Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 50. France Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Cancer Drug based on PARP Inhibitor Revenue Share by Region (2017-2028)
Figure 60. China Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 63. India Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 65. China Taiwan Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 69. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 70. Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 71. Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 72. Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 73. Latin America Cancer Drug based on PARP Inhibitor Sales Share by Country (2017-2028)
Figure 74. Latin America Cancer Drug based on PARP Inhibitor Revenue Share by Country (2017-2028)
Figure 75. Mexico Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 76. Brazil Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 77. Argentina Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Share by Country (2017-2028)
Figure 84. Turkey Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Cancer Drug based on PARP Inhibitor Revenue (2017-2028) & (US$ Million)
Figure 87. Cancer Drug based on PARP Inhibitor Value Chain
Figure 88. Cancer Drug based on PARP Inhibitor Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
Industry Market Size
